Home

Jeffrey Scott Riley

CIK 1487645 · Chief Executive Officer · last filed 2026-07-17

Jeffrey Scott Riley is a Chief Executive Officer who has filed 16 SEC Form 4 insider transactions across 3 companies since 2010. The most recent filing, for GANX, was dated Jul 17, 2026. Across all open-market trades the lifetime net is +$129.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $51.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$51.9K

Companies

3

Total Filings

16

Lifetime Open-Market Net

$129.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GANX Director 30,000 $1.73 $51.9K $115.8K 6 2026-07-17
Theriva Biologics, Inc. (SYN) Delisted Chief Executive Officer 7,505 $1.02 $7.7K $13.6K 6 2016-12-02
Theriva Biologics, Inc. (AEN) Delisted CEO and President — — — $0 4 2012-02-06

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-17 GANX Grant (A) — $0 EDGAR
2025-06-25 GANX Grant (A) — $0 EDGAR
2024-06-26 GANX Grant (A) — $0 EDGAR
2024-04-01 GANX Buy (P) +30,000 $115.8K EDGAR
2023-06-26 GANX Grant (A) — $0 EDGAR
2022-09-22 GANX Grant (A) — $0 EDGAR
2016-12-02 Theriva Biologics, Inc. (SYN) Delisted Grant (A) — $0 EDGAR
2015-12-04 Theriva Biologics, Inc. (SYN) Delisted Grant (A) — $0 EDGAR
2015-01-12 Theriva Biologics, Inc. (SYN) Delisted Grant (A) — $0 EDGAR
2013-01-07 Theriva Biologics, Inc. (SYN) Delisted Buy (P) +2,900 $506 EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.